Unique ID issued by UMIN | UMIN000009139 |
---|---|
Receipt number | R000010713 |
Scientific Title | Effects of Highly Absorptive Curcumin on Inflammation in Chronic Obstructive Pulmonary Disease (HS-Cur COPD study) |
Date of disclosure of the study information | 2012/10/18 |
Last modified on | 2017/04/24 00:05:06 |
Effects of Highly Absorptive Curcumin on
Inflammation in Chronic Obstructive Pulmonary Disease (HS-Cur COPD study)
Effects of HS-Curcumin on COPD
Effects of Highly Absorptive Curcumin on
Inflammation in Chronic Obstructive Pulmonary Disease (HS-Cur COPD study)
Effects of HS-Curcumin on COPD
Japan |
Mild or moderate chronic obstructive pulmonary disease
Medicine in general | Pneumology |
Others
NO
The purpose of this study is to determine the effects of high-absorption curcumin with DDS (drug-delivery system) (Theracurmin) on inflammatory markers in patients with mild or moderate chronic obstructive pulmonary disease.
Efficacy
Serum levels of inflammatory biomarkers such as IL-6, hsCRP, SAA-LDL
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
NO
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Treatment
Food |
Three capsules (1 capsule: 30 mg) of high-absorption curcumin capsule (Theracurmin) are orally administered twice daily (after breakfast and dinner, respectively) for 24 weeks.
Three capsules (1 capsule: 30 mg) of placebo capsule are orally administered twice daily (after breakfast and dinner, respectively) for 24 weeks.
20 | years-old | <= |
85 | years-old | > |
Male and Female
1) Patients with chronic obstructive pulmonary disease at stage 0, I, or II according to the definition by the Japanese Respiratory Society
2) Patients who have never smoked at least for the past 4 months
1) severe lung diseases other than COPD
2) renal insufficiency (Cre >= 4.0mg/dL) or hemodialysis
3) severe hepatic disorder or liver cirrhosis
4) Unstable angina pectoris, acute myocardial infarction, severe coronary heart disease (left main trunk or triple vessel disease)
5) Shock, Heart failure, myocardial infarction, Pulmonary embolism
6) Stroke within 3 months
7) Uncontrolled diabetes (more than 10% of HbA1c)
8) Severe infection or trauma
9) Malnutrition
10) Malignancy
11) Anemia (less than 6 mg/dL of Hb)
12) Use of steroid or antibiotics
13) Intake of curcumin
14) Allergy
15) Pregnancy
16) etc
60
1st name | |
Middle name | |
Last name | Koji Hasegawa |
National Hospital Organization Kyoto Medical Center
Division of Translational Research
1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan
075-641-9161
koj@kuhp.kyoto-u.ac.jp
1st name | |
Middle name | |
Last name | Koji Hasegawa |
National Hospital Organization Kyoto Medical Center
Division of Translational Research
1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan
075-641-9161
koj@kuhp.kyoto-u.ac.jp
National Hospital Organization Kyoto Medical Center
Theravalues Inc.
Profit organization
NO
2012 | Year | 10 | Month | 18 | Day |
Published
Main results already published
2012 | Year | 10 | Month | 15 | Day |
2012 | Year | 10 | Month | 18 | Day |
2012 | Year | 10 | Month | 18 | Day |
2017 | Year | 04 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010713
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |